NEULANDLAB.NSE · Neuland Laboratories Limited

-

Please sign in to comment on NEULANDLAB.NSE

1 Comment

Admin

4 years ago

Neuland Laboratories Limited is currently in a long term uptrend where the price is trading 29.3% above its 200 day moving average.

From a valuation standpoint, the stock is 31.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.3.

Neuland Laboratories Limited's total revenue rose by 20.4% to $2B since the same quarter in the previous year.

Its net income has increased by 140.6% to $267M since the same quarter in the previous year.

Finally, its free cash flow grew by 64.4% to $801M since the same quarter in the previous year.

Based on the above factors, Neuland Laboratories Limited gets an overall score of 5/5.

Exchange	NSE
CurrencyCode	INR
ISIN	INE794A01010
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Market Cap	164B
PE Ratio	54.63
Beta	0.76
Target Price	17600
Dividend Yield	0.1%

ABOUT

Neuland Laboratories Limited

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

NEULANDLAB.NSE · Neuland Laboratories Limited

-

Neuland Laboratories Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Neuland Laboratories Limited using a moving average strategy